FDA approved inclusion of new evidence that Cosentyx significantly slows the progression of joint structural damage at Week 24 versus placebo in those with active psoriatic arthritis (PsA).
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00PR Newswirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngPR Newswire2018-06-19 16:02:332018-06-20 15:32:35Novartis Receives FDA Approval For New Prescribing Information For Blockbuster PsA Treatment Cosentyx
